About the Oncotype DX AR-V7 Nucleus Detect test

Why Order the Oncotype DX AR-V7 Nucleus Detect Test?


Quickly and confidently determine if your mCRPC patient is likely to benefit from an AR-targeted therapy.

The first and only test of its kind to identify patients who will NOT respond to AR-targeted therapies

Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine the next step.

Accurately identify patients resistant to targeted therapies

Not all mCRPC patients respond to androgen receptor (AR)-targeted therapies, like abiraterone and enzalutamide.1 When AR-targeted therapy fails, acquired resistance could be the cause. The only predictive and prognostic test for men with mCRPC, the AR-V7 Nucleus Detect test:

  • Accurately identifies patients who will not benefit from AR-targeted therapies.
  • Is predictive of improved overall survival with taxanes versus AR-targeted therapies.
  • Provides easy-to-interpret results (a positive or negative result).


mCRPC Image


The AR-V7 Nucleus Detect test provides unparalleled specificity by detecting AR-V7 proteins in the nucleus of circulating tumor cells (not cytoplasmic AR-V7 proteins). Find out more about nuclear detection.

Order the test each time the risk of resistance increases

Over time, tumors can adapt (and become resistant) to AR-targeted treatments. The percentage of patients who are nuclear AR-V7+ (an absolute indicator that a patient will not respond to AR-targeted therapies) increases with each exposure to AR-targeted therapies.2

  • Roughly 1 in 5 patients (18%) are nuclear AR-V7+ after receiving abiraterone or enzalutamide.
  • Roughly 1 in 3 patients (31%) are nuclear AR-V7+ after receiving two rounds of AR-targeted therapy.

The percentage of mCRPC patients with the AR splice variant (AR-V7+) increased with continued exposure to AR-targeted therapies2

AR Resistance Graph
Cross-sectional cohort study. Blood samples were collected from 161 patients with mCRPC and tested for the presence of AR-V7.

No intrusive procedures required

A liquid biopsy, the AR-V7 Nucleus Detect test analyzes circulating tumor cells in the patient’s blood. The sample is obtained through a simple blood draw and sent to our clinical laboratory. No intrusive or complicated procedures are required. The results are reported to the ordering physician confirming the patient as either AR-V7+ or AR-V7-. Learn how to order and use the AR-V7 Nucleus Detect test.


1. Antonarakis et al. N Engl J Med. 2014.
2. Scher et al. JAMA Oncol. 2016.

Report Viewer

Take an interactive tour of the Oncotype DX AR-V7 test report.

Start Report Guide

Important Guideline Updates

Learn more about recent changes to guidelines supporting AR-V7 testing in mCRPC patients.




Optimizing Treatment Selection for mCRPC Using Oncotype DX AR-V7 Nucleus Detect Test

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™